

533 Rec'd PCT/PTO 05 OCT 2001

5000

PCT# 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: To Be Assigned

RAZA et al.

Examiner: To Be Assigned

Appln. No.: 09/889,414

Filed: July 17, 2001

FOR: **DRUG COMBINATIONS COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME**

Date: October 5, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Attached is a Form PTO-1449 listing the enclosed documents. The Examiner's attention is called, in particular, to EP 0 521,471, a copy of which is submitted herewith. This is the correct citation of the single document cited in the International Search Report submitted with this application when filed. This document was incorrectly cited as EP 0 521 417 in the ISR, and thus also on the Form PTO-1449 dated July 17, 2001 filed with this application. EP 0 521,471 is correctly cited in the International Preliminary Examination Report and in the application at specification page 4, line 18.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee is under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 009901/0281558 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Respectfully Submitted,


PILLSBURY WINTHROP LLP

By:

Pillsbury Winthrop LLP
1600 Tysons Boulevard
McLean, VA 22120
Washington, D.C. 20005-3918
DJB:amx



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 861-3027
Fax No.: (202) 822-0944



Atty.
Dkt. No.

M#

Client Ref.

0281558

Z70475/UST

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Raza et al.

Appln. No.: 09/889,414

Filing Date: July 17, 2001

Date: October 5, 2001

Page

1

of

1

Examiner: ~~To Be Assigned~~

Group Art Unit: ~~To BE Assig~~

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
<i>MM</i>	HR EP 0 521 471	01/1993	EUROPE	Hirai et al.				
	IR							
	JR							
	KR							
	LR							
	MR							
	NR							
	OR							
	PR							
	QR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

<i>MM</i>	RR	Robert H. Knopp, "Drug treatment of lipid disorders", The New England Journal of Medicine, Vol. 341, 1999, pg. 498-511						
<i>MM</i>	SR	Kantola et al., "Effect of itraconazole on the pharmacokinetics of atorvastatin", Clinical Pharmacology & Therapeutics, Vol. 64, 1998, pg. 58-65						
<i>MM</i>	TR	Neuvonen et al., "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole", Clinical Pharmacology & Therapeutics, Vol. 63, 1998, pg. 332-341						
<i>MM</i>	UR	Neuvonen et al., "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid", Clinical Pharmacology & Therapeutics, Vol. 60, 1996, pg. 54-61						
	VR							
	WR							

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.